We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
- Authors
Choueiri, Toni K; Schutz, Fabio A B; Je, Youjin; Rosenberg, Jonathan E; Bellmunt, Joaquim
- Abstract
Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers. Arterial thromboembolic events (ATE) have been described with these agents, although the overall risk remains unclear. We did a systematic review and meta-analysis to determine the incidence and the relative risk (RR) associated with the use of sunitinib and sorafenib.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 13, p2280
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.27.2757